- Report
- October 2022
- 70 Pages
Africa
From €4231EUR$4,750USD£3,618GBP
- Report
- February 2024
- 181 Pages
Europe
From €4231EUR$4,750USD£3,618GBP
- Report
- August 2026
- 160 Pages
From €2957EUR$3,320USD£2,529GBP
€3697EUR$4,150USD£3,161GBP
- Report
- October 2022
- 177 Pages
From €3073EUR$3,450USD£2,628GBP
- Report
- October 2022
- 174 Pages
North America
From €3073EUR$3,450USD£2,628GBP
- Report
- October 2022
- 181 Pages
Middle East, Africa
From €3073EUR$3,450USD£2,628GBP
- Report
- October 2022
- 205 Pages
Asia Pacific
From €3073EUR$3,450USD£2,628GBP
- Report
- January 2024
- 120 Pages
United States
€3118EUR$3,500USD£2,666GBP
- Report
- April 2023
- 85 Pages
Global
From €3500EUR$4,209USD£3,097GBP
Levemir is a medication used to treat endocrine and metabolic disorders, such as diabetes. It is a long-acting insulin analog, meaning it is a synthetic form of insulin that is designed to mimic the body's natural insulin production. Levemir is used to control blood sugar levels in people with type 1 and type 2 diabetes. It is typically taken once or twice daily, depending on the individual's needs. Levemir is available in both vials and pens, and is typically injected under the skin.
Levemir is a popular medication for treating endocrine and metabolic disorders, and is widely available in many countries. It is manufactured by Novo Nordisk, a Danish pharmaceutical company, and is available in both generic and branded forms. Other companies that produce Levemir include Sanofi, Eli Lilly, and Biocon. Show Less Read more